Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MGTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.32% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 501.52M USD | Price to earnings Ratio - | 1Y Target Price 23.6 |
Price to earnings Ratio - | 1Y Target Price 23.6 | ||
Volume (30-day avg) 695087 | Beta 1.24 | 52 Weeks Range 3.85 - 8.75 | Updated Date 04/2/2025 |
52 Weeks Range 3.85 - 8.75 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.56 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) -147.22% |
Management Effectiveness
Return on Assets (TTM) -34.41% | Return on Equity (TTM) -143.48% |
Valuation
Trailing PE - | Forward PE 40.98 | Enterprise Value 466884405 | Price to Sales(TTM) 15.07 |
Enterprise Value 466884405 | Price to Sales(TTM) 15.07 | ||
Enterprise Value to Revenue 14.03 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 78854896 | Shares Floating 31236017 |
Shares Outstanding 78854896 | Shares Floating 31236017 | ||
Percent Insiders 39.24 | Percent Institutions 58.89 |
Analyst Ratings
Rating 4.6 | Target Price 21 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC is a gene therapy company founded in 2015. It focuses on developing and commercializing gene therapies for serious diseases. It has partnerships with Johnson & Johnson and Sanofi.
Core Business Areas
- Ophthalmology: Developing gene therapies for inherited retinal diseases.
- Salivary Gland Disease: Developing gene therapies for radiation-induced xerostomia.
- Neurodegenerative Diseases: Developing gene therapies for neurodegenerative diseases such as Parkinson's Disease and ALS.
Leadership and Structure
Alexandria Forbes is the President and CEO. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- AAV-RPGR: Gene therapy for X-linked retinitis pigmentosa (XLRP). Currently in clinical development. Competitors include Spark Therapeutics (Roche).
- AAV2-hAQP1: Gene therapy for radiation-induced xerostomia. Currently in clinical development. Limited competition in this niche area.
- Virally transduced MSC-NTF cells (PD-101/NMTsig):: Gene therapy for Parkinson's Disease. Competitors include Neuronyx.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, with increasing investment and regulatory approvals. The industry is highly competitive.
Positioning
MeiraGTx is a mid-sized player focused on specific rare diseases with strong partnerships. Its competitive advantages include its technology platform and collaboration network.
Total Addressable Market (TAM)
The gene therapy market is projected to reach billions of dollars. MeiraGTx is targeting specific diseases within this larger market.
Upturn SWOT Analysis
Strengths
- Strong partnerships with Johnson & Johnson and Sanofi
- Proprietary gene therapy platform
- Focus on rare and underserved diseases
- Experienced management team
Weaknesses
- Dependence on clinical trial success
- High cash burn rate
- Limited commercial infrastructure
- Small market capitalization
Opportunities
- Positive clinical trial results
- Regulatory approvals for its gene therapies
- Expansion into new disease areas
- Potential for acquisitions or partnerships
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Financing risks
Competitors and Market Share
Key Competitors
- SNY
- LLY
- RHHBY
Competitive Landscape
MeiraGTx competes with larger pharmaceutical companies in the gene therapy space. Its advantages are its focus on specific rare diseases and strong partnerships. Disadvantages include limited resources compared to competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by pipeline development and partnerships.
Future Projections: Future growth depends on clinical trial success and regulatory approvals for its lead gene therapy candidates. Analyst estimates vary widely.
Recent Initiatives: Advancing clinical trials for XLRP and radiation-induced xerostomia. Expanding collaborations to new disease areas.
Summary
MeiraGTx is a gene therapy company with promising partnerships and a focus on rare diseases. Its success depends heavily on clinical trial outcomes and regulatory approvals. The company is pre-revenue, resulting in net losses. It needs to manage its cash burn rate carefully.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 375 | Website https://meiragtx.com |
Full time employees 375 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.